AMERICAN BIO MEDICA CORPORATION (OTCMKTS:ABMC) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

ME Staff 8-k
-
0
AMERICAN BIO MEDICA CORPORATION (OTCMKTS:ABMC) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

AMERICAN BIO MEDICA CORPORATION (OTCMKTS:ABMC) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
ITEM 5.02.

DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.

Resignation of Director
On February 5, 2021, Chaim Davis notified American Bio Medica Corporation (the \”Company\”) that he was resigning from the Company\’s Board of Directors (the \”Board\”) effective immediately. Mr. Davis’s decision to resign was for a personal reason, so as to free up his time to focus on his other business commitments. His resignation was not the result of any disagreement with the Company or its management with respect to any matter relating to the Company\’s operations, policies or practices.
Mr. Davis also served as the Chairman of the Board of Directors and served on the Audit, Compensation and Nominating Committees of the Board of Directors.
The Company’s remaining board members (Jean Neff, Peter Jerome and CEO Melissa Waterhouse) will promptly begin a search for a new independent director to fill the vacancy created by Mr. Davis’s resignation. The role of Chairman of the Board will remain vacant until an experienced and qualified successor is identified. As provided under the Company’s Bylaws, in the absence of the appointment of a new Chairman of the Board and until a new Chairman is appointed, the Company’s Chief Executive Officer, Melissa Waterhouse, will assume the responsibilities of the Chairman of the Board.

About AMERICAN BIO MEDICA CORPORATION (OTCMKTS:ABMC)

American Bio Medica Corporation develops, manufactures and sells immunoassay tests, primarily for the immediate, point of collection testing (POCT) for drugs of abuse (DOA) in urine and oral fluids. The Company’s DOA POCT products offer employers, law enforcement, government, healthcare and education professionals to identify illicit drug use. In addition to the manufacture and sale of DOA POCT products, the Company provides bulk test strip manufacturing services to unaffiliated third parties on a contract basis. Its Rapid Drug Screen (RDS) is a POCT product that detects the presence or absence of 2 to 10 DOA simultaneously in a single urine specimen. The Rapid ONE product line consists of single drug tests, each of which tests for the presence or absence of a single drug of abuse in a urine specimen. The RDS InCup is a POCT product that detects the presence or absence of 1 to 12 DOA in a single urine specimen. The POCT products for oral fluid-based DOA testing include OralStat.